Elicio Therapeutics (ELTX) Price & Analysis

Compare

213 Followers

ELTX Stock Chart & Stats

$8.05

$0.10(1.66%)

At close: Jan 08 4:00 PM EST

$8.05

$0.10(1.66%)

Day’s Range― - ―

52-Week Range$4.60 - $12.62

Previous CloseN/A

Volume37.28K

Average Volume (3M)77.23K

Market Cap

$149.50M

Enterprise Value$116.79M

Total Cash (Recent Filing)$20.61M

Total Debt (Recent Filing)$5.34M

Price to Earnings (P/E)―

Beta0.68

Next Earnings

Mar 27, 2026

EPS Estimate

-0.45

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.60

Shares Outstanding16,338,284

10 Day Avg. Volume85,490

30 Day Avg. Volume77,231

Financial Highlights & Ratios

PEG Ratio0.03

Price to Book (P/B)-5.50

Price to Sales (P/S)0.00

P/FCF Ratio-1.68

Enterprise Value/Market Cap0.78

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-134.86

Enterprise Value/Ebitda-2.67

Forecast

1Y Price Target

$15.50

Price Target Upside92.55% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical TrialsELI-002 7P elicits a meaningfully greater T cell response, potentially leading to longer survival and reduced disease progression.

Financial ResourcesFinancial resources reported should be sufficient to fund operations through the release of significant clinical trial data.

Stock ValuationThe stock is currently trading around 3X multiple to probability-adjusted peak sales with a potential increase in valuation if Phase 2 data is positive.

Bears Say

Investor SentimentStock slightly pulled back on that day as some investors expected early stoppage of the trial due to a low hazard ratio at this interim analysis.

Trial Data TransparencyThe company remains blinded to the Phase 2 trial clinical efficacy outcomes.

Trial TimelineThe readout timeline got postponed for the second time in 2025, likely indicates longer than expected DFS in the treatment arm.

Elicio Therapeutics News

Elicio Therapeutics’ ELI-002 7P shows antigen spreading in Phase 2 trial

Elicio Therapeutics (ELTX) announced that analysis of a subset of patients in the ongoing Phase 2 AMPLIFY-7P trial...

3h ago

ELTX

Elicio Therapeutics appoints Marc Wolfgang as CTO

Elicio Therapeutics (ELTX) announced the appointment of Marc Wolfgang, M.S. as Chief Technology Officer. He most recently served...

22d ago

ELTX

Elicio Therapeutics files to sell 103,225 shares of common stock for holders

17:05 EST Elicio Therapeutics (ELTX) files to sell 103,225 shares of common stock for holders Published first on...

28d ago

ELTX

Elicio Therapeutics Reports Q3 2025 Financial Results

Elicio Therapeutics, Inc ( ($ELTX) ) has released its Q3 earnings. Here is a breakdown of the information...

28d ago

ELTX

Elicio Therapeutics announces additional data from Phase 2 AMPLIFY-7P trial

Elicio Therapeutics (ELTX) announced additional immunogenicity data from the ongoing Phase 2 AMPLIFY-7P trial evaluating ELI-002 7P in...

1M ago

ELTX

Elicio announces preliminary analysis from Phase 2 AMPLIFY-7P trial

Elicio Therapeutics (ELTX) announced that preliminary analysis of patients in the ongoing Phase 2 AMPLIFY-7P trial indicated that...

2M ago

ELTX

Elicio Therapeutics announces investigator-initiated Phase 1 trial of ELI-002 7P

Elicio Therapeutics (ELTX) announced the planned initiation of an investigator-initiated Phase 1 neoadjuvant study of ELI-002 7P in...

2M ago

ELTX

Elicio Therapeutics reports inducement grants

Elicio Therapeutics (ELTX) announced that on September 15, 2025, Elicio granted an aggregate of 9,800 inducement stock options...

3M ago

ELTX

Elicio Therapeutics Announces Promising Phase 2 Vaccine Results

An announcement from Elicio Therapeutics ( ($ELTX) ) is now available. On September 17, 2025, Elicio Therapeutics announced...

3M ago

ELTX

Elicio reports ELI-002 7P induced T cell responses in 99% of patients

Elicio Therapeutics (ELTX) announced immunogenicity testing data showing that approximately 99% of evaluable patients enrolled in its ongoing...

3M ago

ELTX

Elicio Therapeutics Publishes Promising Phase 1 Study Data

Elicio Therapeutics ( ($ELTX) ) just unveiled an announcement. On August 12, 2025, Elicio Therapeutics announced the publication...

4M ago

ELTX

Elicio announces publication of ELI-002 updated AMPLIFY-201 Phase 1 data

Elicio Therapeutics (ELTX) announced the publication of follow-up data from the Phase 1 AMPLIFY-201 study evaluating ELI-002 in...

4M ago

ELTX

Elicio Therapeutics Reports Q2 2025 Financial Results

Elicio Therapeutics, Inc ( ($ELTX) ) has released its Q2 earnings. Here is a breakdown of the information...

4M ago

ELTX

Elicio Therapeutics Advances Phase 2 AMPLIFY-7P Study

The latest announcement is out from Elicio Therapeutics ( ($ELTX) ). On August 5, 2025, Elicio Therapeutics announced...

4M ago

ELTX

ELTX FAQ

What was Elicio Therapeutics’s price range in the past 12 months?

Elicio Therapeutics lowest stock price was $4.60 and its highest was $12.62 in the past 12 months.

What is Elicio Therapeutics’s market cap?

Elicio Therapeutics’s market cap is $149.50M.

When is Elicio Therapeutics’s upcoming earnings report date?

Elicio Therapeutics’s upcoming earnings report date is Mar 27, 2026 which is in 106 days.

How were Elicio Therapeutics’s earnings last quarter?

Elicio Therapeutics released its earnings results on Nov 13, 2025. The company reported -$0.6 earnings per share for the quarter, missing the consensus estimate of -$0.48 by -$0.12.

Is Elicio Therapeutics overvalued?

According to Wall Street analysts Elicio Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Elicio Therapeutics pay dividends?

Elicio Therapeutics does not currently pay dividends.

What is Elicio Therapeutics’s EPS estimate?

Elicio Therapeutics’s EPS estimate is -0.45.

How many shares outstanding does Elicio Therapeutics have?

Elicio Therapeutics has 16,338,284 shares outstanding.

What happened to Elicio Therapeutics’s price movement after its last earnings report?

Elicio Therapeutics reported an EPS of -$0.6 in its last earnings report, missing expectations of -$0.48. Following the earnings report the stock price went down -0.871%.

Which hedge fund is a major shareholder of Elicio Therapeutics?

Currently, no hedge funds are holding shares in ELTX

Elicio Therapeutics Stock Smart Score

Neutral

Analyst Consensus

Moderate Buy

Average Price Target:
$15.50 (92.55% Upside)

Technicals

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

87.48%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Elicio Therapeutics

Elicio Therapeutics (ELTX) is a biotechnology company focused on developing innovative immunotherapies to treat cancer and other diseases. The company operates in the biopharmaceutical sector and is dedicated to leveraging its proprietary Amphiphile platform to enhance the potency and durability of immune responses. Elicio's core products include a pipeline of cancer vaccines and immune-modulating therapies designed to target and eliminate cancer cells effectively.

Elicio Therapeutics (ELTX) Earnings & Revenues

Historic Earnings Reports

ELTX Stock 12 Month Forecast

Average Price Target

$15.50

▲(92.55% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","7":"$7","11":"$11","15":"$15","19":"$19"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$18.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$15.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$13.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,7,11,15,19],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.29,9.959999999999999,10.629999999999999,11.299999999999999,11.969999999999999,12.639999999999999,13.309999999999999,13.98,14.649999999999999,15.32,15.989999999999998,16.66,17.33,{"y":18,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.29,9.767692307692307,10.245384615384614,10.723076923076922,11.20076923076923,11.678461538461537,12.156153846153845,12.633846153846154,13.111538461538462,13.589230769230769,14.066923076923077,14.544615384615383,15.022307692307692,{"y":15.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.29,9.575384615384614,9.86076923076923,10.146153846153846,10.43153846153846,10.716923076923077,11.002307692307692,11.287692307692307,11.573076923076922,11.858461538461539,12.143846153846154,12.42923076923077,12.714615384615385,{"y":13,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.05,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.59,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.2,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.1,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.31,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.95,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.02,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.75,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.72,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.98,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.35,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.96,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.29,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >